SCHEMBL2815633

SCHEMBL2815633

N#CC1(c2ccc([N+](=O)[O-])cc2)CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PGR P06401 1/20 0.43
SCD O00767 1/20 0.42
MAPT P10636 4/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HTR1E P28566 1/20 0.41
S1PR3 Q99500 1/20 0.41
LMNA P02545 5/20 0.40
TP53 P04637 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814643 0.98 ALDH1A1 (0.44) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL3047350 0.95 PGR (0.43) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL1769324 0.91 PGR (0.46) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL5475184 0.86 SCD (0.42) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL3897910 0.84 L3MBTL1 (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2PGR
SCHEMBL2876866 0.84 PDE4A (0.41) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL521393 0.84 ADRB1 (0.44) PGRSCDOPRM1
SCHEMBL2814607 0.80 KDM1A (0.49) ALDH1A1KMT2APGRLMNAPOLB
SCHEMBL10574972 0.77 MEN1 (0.46) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL24992890 0.77 ALDH1A1 (0.44) ALDH1A1MEN1KMT2ASCDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9403804-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-08-02 US disclosed
US-9403804-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-08-02 US disclosed
US-9403804-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-08-02 US disclosed
US-9394289-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 US disclosed
EP-2016058-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-01-06 EP disclosed
EP-2016058-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-01-06 EP disclosed
US-20140378457-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-12-25 US disclosed
US-20140329815-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-11-06 US disclosed
US-20140329815-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-11-06 US disclosed
US-20140329815-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-11-06 US disclosed
EP-2016058-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica, N.V. (BE) 2009-01-21 EP disclosed
WO-2008117175-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2008-10-02 WO disclosed
WO-2007124322-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
WO-2007124322-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
US-20070249608-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed
US-20070249608-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed
US-20070249608-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed
EP-1811998-A1 TRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2007-08-01 EP disclosed
WO-2006047256-A1 TRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378457-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES ALDH1A1 4702/4885MEN1 740/4885KMT2A 844/4885
US-20070249680-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES ALDH1A1 4702/4885MEN1 740/4885KMT2A 844/4885
US-20070249608-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES ALDH1A1 4702/4885MEN1 740/4885KMT2A 844/4885
US-20140329815-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES ALDH1A1 4702/4885MEN1 740/4885KMT2A 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.